Organized by Quantum International Corp., the event aims to serve as a bridge connecting outstanding companies with the global capital markets. During the event, Dr. Chang will represent TaiMed Biologics in a series of one-on-one meetings with leading international institutional investors, asset management firms, and corporate innovation groups. Over the two-day program, Dr. Chang will provide a comprehensive overview of the Company’s operations, financial performance, as well as the latest business developments and R&D progress, highlighting TaiMed’s strong capabilities in innovative biologics and its global expansion potential.
Dr. Chang is also scheduled to engage in in-depth discussions with several prominent international institutional investors, including major sovereign wealth funds from the Middle East, Switzerland, the United Kingdom, and Singapore. Many of these representatives have pre-arranged meetings to gain insights into TaiMed Biologics’ latest R&D progress and future outlook, with the aim of exploring potential collaboration opportunities across multiple areas.
Notably, leading Middle Eastern investment institutions are increasingly focused on healthcare and life sciences, actively seeking companies with technological advantages and the potential to become “global industry champions” with the support of Abu Dhabi’s strategic resources. This investment focus aligns closely with TaiMed Biologics’ positioning as a premier innovative biopharmaceutical company.
By participating in the QIC CEO Week, TaiMed Biologics aims to further enhance its visibility among global institutional investors, actively expand its access to international capital markets, and accelerate opportunities for global licensing partnerships, thereby creating long-term value for shareholders.
Contact CDMO Service